
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
The University of Iowa Cancer Center, Iowa City, Iowa 52242 [C. P. B., G. H. C., B. A. W., R. J. H.]; CALGB Statistical Center, Durham, North Carolina 27710 [S. H., V. H.]; Lakeland Medical Center, St. Joseph, Michigan 49085 [E. L.]; Syracuse Hematology-Oncology Community Clinical Oncology Program, State University of New York Health Science Center at Syracuse, Syracuse, New York 13217 [J. J. K.]; North Shore University Hospital, Manhasset, New York 11030 [V. V.]; and Bowman Gray School of Medicine, Winston-Salem, North Carolina 27157 [E. P.]
The purpose of this study was to determine the maximum tolerated dose and dose-limiting toxicities of fish oil fatty acid capsules containing
-3 fatty acid ethyl esters. Twenty-two patients with neoplastic disease not amenable to curative therapy who had lost 2% of body weight over a previous 1 month time period were given an escalating dose of fish oil fatty acids. The maximum tolerated dose was found to be 0.3 g/kg per day of this preparation. This means that a 70-kg patient can generally tolerate up to 21 1-g capsules/day containing 13.1 g of eicosapentaenoic acid + docosahexaenoic acid, the two major
-3 fatty acids. Dose-limiting toxicity was gastrointestinal, mainly diarrhea, and a poorly described toxicity designated as "unable to tolerate in esophagus or stomach." A patient with chronic lymphocytic leukemia taking the fish oil provided an unusual opportunity to perform a detailed biochemical study of the effect of fish oil capsules on the lipids of malignant cells at several sequential time points in treatment. Studies of the malignant lymphocytes, serum, and whole blood of this one patient revealed an increase in eicosapentaenoic acid, the major component of the fish oil capsules, during fish oil capsule treatment. This study provides a scientific basis for the selection of
-3 fatty acid doses for future studies in cancer. The maximum tolerated dose found is considerably higher than anticipated from published studies of many human diseases. The observation of a modification of the lipids of leukemic cells, serum, and blood in a patient with chronic leukemia provides a biochemical basis for a possible effect of fish oil supplements on cancer cachexia and tumor growth.
This article has been cited by other articles:
![]() |
J. L Hutton, L. Martin, C. J Field, W. V Wismer, E. D Bruera, S. M Watanabe, and V. E Baracos Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1163 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Q. Ding, B. Liu, J. L. Vaught, R. D. Palmiter, and S. E. Lind Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol. Cancer Ther., July 1, 2006; 5(7): 1864 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Siddiqui, D. Pandya, K. Harvey, and G. P. Zaloga Nutrition Modulation of Cachexia/Proteolysis Nutr Clin Pract, April 1, 2006; 21(2): 155 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Davis Eicosapentaenoic Acid: The Answers Are Not All In J. Clin. Oncol., June 1, 2005; 23(16): 3854 - 3854. [Full Text] [PDF] |
||||
![]() |
D. H. Jho, S. M. Cole, E. M. Lee, and N. J. Espat Role of Omega-3 Fatty Acid Supplementation in Inflammation and Malignancy Integr Cancer Ther, June 1, 2004; 3(2): 98 - 111. [Abstract] [PDF] |
||||
![]() |
D. H. Wheaton, D. R. Hoffman, K. G. Locke, R. B. Watkins, and D. G. Birch Biological Safety Assessment of Docosahexaenoic Acid Supplementation in a Randomized Clinical Trial for X-Linked Retinitis Pigmentosa Arch Ophthalmol, September 1, 2003; 121(9): 1269 - 1278. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Dixon Integrative Tumor Board: Colon Cancer with Liver Metastases Integr Cancer Ther, June 1, 2003; 2(2): 173 - 180. [PDF] |
||||
![]() |
E. Bruera, F. Strasser, J. L. Palmer, J. Willey, K. Calder, G. Amyotte, and V. Baracos Effect of Fish Oil on Appetite and Other Symptoms in Patients With Advanced Cancer and Anorexia/Cachexia: A Double-Blind, Placebo-Controlled Study J. Clin. Oncol., January 1, 2003; 21(1): 129 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |